Birmingham, AL, United States of America

George M Shaw

USPTO Granted Patents = 20 

 

 

Average Co-Inventor Count = 5.4

ph-index = 3

Forward Citations = 73(Granted Patents)


Location History:

  • Birmingham, AL (US) (1998 - 2021)
  • Wallingford, PA (US) (2016 - 2023)
  • Philadelphia, PA (US) (2018 - 2023)

Company Filing History:

goldMedal7 out of 2,007 
 
Duke University
 patents
silverMedal7 out of 2,595 
 
University of Pennsylvania
 patents
bronzeMedal5 out of 580 
 
The Uab Research Foundation
 patents
45 out of 3,435 
 
National Institutes of Health, a Component of the US Dept. of Health & Human Services
 patents
54 out of 516 
 
University of Alabama
 patents
63 out of 3,682 
 
The Johns Hopkins University
 patents
73 out of 1,153 
 
Vanderbilt University
 patents
83 out of 287 
 
Triad National Security, LLC
 patents
92 out of 574 
 
Los Alamos National Security, LLC
 patents
102 out of 818 
 
Boston University
 patents
112 out of 5,303 
 
Leland Stanford Junior University
 patents
122 out of 1,215 
 
The United States of America As Represented by the Department of Health
 patents
131 out of 15,458 
 
University of California
 patents
141 out of 1,269 
 
University of North Carolina at Chapel Hill
 patents
151 out of 240 
 
The Administrators of the Tulane Educational Fund
 patents
161 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 1998-2025

Loading Chart...
Loading Chart...
Loading Chart...
20 patents (USPTO):

Title: **George M Shaw: A Pioneer in Hepatitis C Vaccine Development**

Introduction

George M Shaw is an innovative inventor based in Birmingham, Alabama, who has made significant contributions to medical research, particularly in the field of vaccines. With a total of 19 patents to his name, his work focuses on advancing our understanding and treatment of hepatitis C virus (HCV), a critical concern in global health.

Latest Patents

Shaw's latest patents reflect his commitment to finding effective solutions against HCV. His inventions include a "Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus," which pertains to compositions and methods aimed at inducing an adaptive immune response against HCV. This patent outlines compositions that may include a nucleoside-modified nucleic acid molecule encoding a HCV antigen along with an adjuvant, highlighting his innovative approach to vaccine development. Another prominent patent is focused on "Hepatitis C virus gene sequences and methods of use therefor," which also aims to induce a robust immune response against HCV through similar sophisticated compositions.

Career Highlights

Throughout his illustrious career, George M Shaw has worked at prestigious institutions such as Duke University and the University of Pennsylvania. These respected organizations have provided a platform for his research endeavors, aiding in the development of groundbreaking vaccines that contribute to infectious disease management.

Collaborations

Collaboration has been a key component of Shaw's success. He has worked alongside renowned scientists, including Beatrice H Hahn and Feng Gao, exchanging knowledge and expertise that enhances the quality and impact of their collective research efforts.

Conclusion

George M Shaw's contributions to the field of vaccine development are noteworthy and demonstrate his role as a leading inventor in the fight against hepatitis C. As he continues to innovate and collaborate, his work holds promise for improving health outcomes for individuals affected by this virus, solidifying his legacy in medical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…